CS Group (OTCQB: CSDX) announced the appointment of Shah Teelani & Associates, a Dubai-based PCAOB-registered auditor, to consolidate and audit the 2025 financial statements of CS Diagnostics Corp., CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH. This move underscores the Group's commitment to strengthening financial governance, regulatory compliance, and transparency as it executes an international expansion strategy across the United States, GCC region, and Europe.
The engagement involves Shah Teelani & Associates overseeing the consolidation of financial statements for the publicly traded entity and its subsidiaries. Management emphasized that appointing a PCAOB-registered audit firm is a significant step in aligning the Group's financial reporting structure with U.S. public company standards while integrating its growing international operations under a unified reporting framework. The consolidated audit is expected to enhance financial clarity, streamline reporting processes, and build investor confidence.
The 2025 consolidated financial review will encompass operations related to the MEDUSA hygiene and disinfectant platform and international distribution expansion. MEDUSA is a smart disinfectant and hygiene solutions platform expanding into wet wipes and liquid formulations for institutional and consumer use. The Group continues to focus on expanding manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its broader global growth roadmap.
Mohammad Essayed, Group Chief Financial Officer, stated, "Engaging Shah Teelani & Associates as our PCAOB-registered auditor represents an important milestone in CS Group's evolution as a publicly traded company. As we scale operations across multiple regions, it is essential that our financial reporting structure reflects institutional-grade standards, transparency, and regulatory compliance. This appointment strengthens our governance foundation and supports our long-term growth strategy."
CS Diagnostics Corp. (OTCQB: CSDX) is a medical technology company advancing a dual-focus platform across infection control and oncology, targeting high-priority global healthcare markets. The Company's portfolio includes MEDUSA and CS Protect-Hydrogel, a tissue spacer designed to protect healthy organs during prostate cancer radiotherapy. CSDX is progressing through key commercialization milestones, including strategic manufacturing partnerships, multi-region launches across the GCC and Europe, diversified B2B and B2C distribution channels, global logistics agreements, and a growing intellectual property and regulatory roadmap.
For further information, please visit https://group-csd.com/ or contact Mohammad Essayed via the company's website.
